RE:RE:RE:RE:AcquistionSubject to adjustments set out in the Term Sheet, the aggregate purchase price expected to be paid by the Company for the Purchased Shares shall consist of the following: (i) approximately $200,000 in cash on the closing date of the Acquisition, defined below (the “Closing Date”); (ii) 6,000,000 common shares of Kane Biotech (each a “Kane Share”), which shall be held in escrow and released pursuant to an escrow agreement on the date that is 36 months from the Closing Date; (iii) 6,000,000 warrants to purchase Kane Shares at a price of $0.25 per Kane Share for a period of 36 months; (iv) on the date that is 18 months from the Closing Date, approximately $920,000 in cash which, at the option of Kane Biotech, may be satisfied by issuing the equivalent number of Kane Shares; and (v) on the date that is 36 months from the Closing Date, approximately $1,380,000 in cash which, at the option ...